OR Productivity is the developer of FreeHand – a low-cost surgical robotic platform for robotic-assisted minimally invasive (keyhole) procedures. It has a 'Product as a Service' business model generating high margin recurring income. We are now looking to deliver FreeHand to all viable international markets and continue developing a wider family of products.

OR Productivity

98% INVESTMENT RAISED
Maturity

Sales and licensing

Sector Medical Device
Market

Minimally Invasive (keyhole) Surgery

Equity
EIS Advance Assurance received
440821Funds Raised
450000Target
investors
Campaign finished

Previous Next

What our experts say

The final rating*

Team
84%
Science
74%
Innovation
75%
Business
75%
Finances
60%
*The BioExpert Network is an independent and exclusive network of industry experts in the sectors of life science and investment. Only proposals which receive the most positive responses, in terms of novel concepts, scientific validity and financial perspective successfully progress to funding campaign stage on the Capital Cell online platform. The opinions of our BioExpert Network cannot be relied upon as a guide to the likely successes of the company. Investors need to conduct their own due diligence and analysis before deciding whether to invest in a Capital Cell listed business.
Globally applicable robotic systems for minimally invasive surgery positioned to become a significant Medical Devices business

OR Productivity is the developer of FreeHand – a low-cost surgical robotic platform for robotic-assisted minimally invasive (keyhole) procedures. We have a 'Product as a Service' business model generating high margin recurring income. We are ready to drive commercialisation, particularly in the United States through developing key strategic partners. We intend to conduct further clinical studies to allow us to disseminate convincing clinical and economic data. We will complete the launch of our new products adding to the range of robots based on the FreeHand platform technology.

Our team

Executive Team

Jeremy Russell
CEO

Jeremy has 25 years blue chip R&D and manufacturing experience starting with Glaxo. He was Technical Director at Biocompatibles before becoming R&D Director for Smiths Medical International for 11 years. He has a PhD in cancer research and is a Fellow of the Royal Society of Chemistry with over 30 patents and publications. Jeremy has launched over 75 new products in his career and during his time with Smiths Medical evaluated countless prospective products and technologies as part of the Smiths Group investment strategy. He led product and process design and re-engineering and throughout his career has delivered new innovative products to meet developing market demand.

David Pinto
Director of Technical projects and programmes

David is a Chartered Mechanical Engineer with 20 years medical device new product development experience matched with extensive project management expertise. He worked for Jeremy as R&D Manager at Smiths Medical for 11 years where he was responsible for a design and development team of 18 people. David has taken in excess of 35 products from R&D through to product launch. He is highly attuned to the requirements set out in the medical device regulatory framework which enables the Company to supply CE, UL and FDA registered devices into the market.

Ernst Schaaf
Director of Sales, Europe

Ernst is a seasoned sales, marketing and distribution manager with 30 years experience in managing pharmaceutical and medical device products. Having originally studied Economics and Marketing in Frankfurt he went on to work with Abbott and BOC Health Care before becoming the Managing Director at ATS Medizintechnik which sold blood management and infusion therapy products. In his career Ernst has developed an extensive pan-European network, whilst taking a hands on approach with the product, and in training and supporting new distributors.